whether Fosamax (alendronate) and other bisphosphonates increase the risk of atrial fibrillation

June 2008

See FDA's updated safety analysis concerning bisphophonates and atrial fibrillation

Patients are asking whether Fosamax (alendronate) and other bisphosphonates increase the risk of atrial fibrillation.

This first came up last year when researchers noted an increase in A fib in patients getting IV zoledronic acid (Reclast).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

More patients AND PARTNERS will get Suprax for gonorrhea
ADHD American Heart Assoc statement is raising a furor because it implies that ALL children on ADHD drugs need an ECG
Migraine Treximet, a new sumatriptan and naproxen combination tablet for migraines
Gastroenterology Amitiza (lubiprostone) will come in a new lower strength for treating irritable bowel syndrome with constipation (IBS-C)
Gastroenterology Cimzia (CIM-zee-uh) is a new biologic therapy for Crohn's disease
Gastroenterology Relistor (REL-i-store) will offer a new option for treating opioid-induced constipation
Hypertension how to treat resistant hypertension
Respiratory & Allergy Patanase (olopatadine) and Omnaris (ciclesonide) nasal sprays for allergic rhinitis
Geriatrics Vitamin D is being used more in the elderly to PREVENT falls
Pediatrics treating metabolic syndrome in kids
Bisphosphonates whether Fosamax (alendronate) and other bisphosphonates increase the risk of atrial fibrillation
Supplements glucosamine alone or with chondroitin can interact with warfarin
Cardiology Is it better to use an ACE inhibitor, angiotensin receptor blocker (ARB), or both in patients at risk for heart disease?